In Tapia's study, BCL-2 positivity was observed in 71% of PCNS-DLBCL cases, but it had no relationship with outcome.[24] In contrast, Kim and Makino studies demonstrated that BCL-2 overexpression had a significantly poorer OS in patients with PCNS-DLBCL.[25,26] BCL-2 expression was detected in 69.0% of cases in our series, which was within the range described previously. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.